AVDL Share Price Performance
US$12.74
-3.00 (-19.06%)
26.1% undervalued intrinsic discount
US$17.25
Fair Value
Price US$12.74
AnalystConsensusTarget US$17.25
Fair ValueUS$17.25
Share PriceUS$12.74
26.1% undervalued intrinsic discount
AVDL Community Narratives
AN
Fair Value US$17.25 26.1% undervalued intrinsic discount
New Indications And Patient Focus Will Deliver Long-Term Market Strength
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
Recent AVDL News & Updates
No updates
Avadel Pharmaceuticals plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.27
- Gross Margin
- 90.06%
- Net Profit Margin
- -13.58%
- Debt/Equity Ratio
- 50.6%
Avadel Pharmaceuticals plc Competitors
About AVDL
- Founded
- 2015
- Employees
- 188
- CEO
- WebsiteView website
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Irish Market Performance
- 7 Days: -1.2%
- 3 Months: 4.9%
- 1 Year: 21.8%
- Year to Date: 17.0%
Over the last 7 days, the market has dropped 1.2%, driven by a loss of 4.3% in the Consumer Staples sector. In the last year, the market is actually up 22%. Looking forward, earnings are forecast to grow by 7.1% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading